Clinical evaluations
EPIT safety evaluation considered both local and systemic adverse
reactions reported weekly by owners. Primary and secondary efficacy
outcomes were established. Figure 2 represents the evaluation timeline.
Primary outcomes:
- Owner-assessed pruritus manifestations (validated pruritus visual
analogue scale - PVAS10)42,43.
- Veterinarian-assessed skin lesions (validated 2D investigator’s global
assessment graphic - 2D-IGA)44.
- Owner global assessment of treatment efficacy
(OGATE)45.
Secondary outcomes:
Owner-reported QoL survey46.
Allergen-specific IgE serology (LETIPharma S.L.U.).